EGFR and lung adenocarcinoma: Therefore, there is an urgent need for a reliable, safe, convenient, and cost-effective method for the non-invasive prediction of EGFR mutation status in lung adenocarcinoma patients, to assist clinicians in selecting appropriate patients for EGFR-TKI treatment, support individualized decision-making, maximize the prognosis of the patient, and also avoid waste of medical resources.